Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 10/20 | 0.74 |
| ▸ | KCNH2 | Q12809 | 9/20 | 0.74 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.41 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | GYS1 | P13807 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MYLK | Q15746 | 1/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3625695 | 0.89 | KCNA5 (0.62) | KCNA5KCNH2GRIA2GRIA4ALDH1A1 | |
| SCHEMBL3623830 | 0.85 | KCNA5 (1.00) | KCNA5KCNH2GRIA2GRIA4ALDH1A1 | |
| SCHEMBL3620578 | 0.82 | KCNA5 (0.55) | KCNA5KCNH2ALDH1A1KDM4ELMNA | |
| SCHEMBL3481278 | 0.80 | KCNA5 (0.54) | KCNA5KCNH2ALDH1A1KDM4ELMNA | |
| SCHEMBL2641192 | 0.79 | KCNA5 (0.54) | KCNA5KCNH2GRIA2GRIA4ALDH1A1 | |
| SCHEMBL3622694 | 0.78 | KCNA5 (0.51) | KCNA5KCNH2KDM4E | |
| SCHEMBL3622231 | 0.77 | GABRA1 (0.52) | KCNA5KCNH2ALDH1A1KDM4EHPGD | |
| SCHEMBL2641302 | 0.76 | KCNA5 (0.52) | KCNA5KCNH2ALDH1A1KDM4ELMNA | |
| SCHEMBL1385042 | 0.76 | KCNA5 (0.82) | KCNA5KCNH2ALDH1A1KDM4ELMNA | |
| SCHEMBL2168453 | 0.75 | KCNA5 (0.58) | KCNA5KCNH2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1667973-B1 | QUINOLINE POTASSIUM CHANNEL INHIBITORS | MERCK SHARP & DOHME (US) | 2013-12-04 | — | — | EP | claimed |
| JP-4794445-B2 | — | — | 2011-10-19 | — | — | JP | claimed |
| US-7825131-B2 | Quinoline potassium channel inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-11-02 | — | — | US | claimed |
| US-20070078154-A1 | Quinoline potassium channel inhibitors | MERCK SHARP & DOHME CORP. | 2007-04-05 | — | — | US | claimed |
| EP-1667973-A2 | QUINOLINE POTASSIUM CHANNEL INHIBITORS | Merck & Co., Inc. (US) | 2006-06-14 | — | — | EP | claimed |
| WO-2005030792-A2 | QUINOLINE POTASSIUM CHANNEL INHIBITORS | MERCK & CO., INC. (US) | 2005-04-07 | — | — | WO | claimed |
| EP-1667973-B1 | QUINOLINE POTASSIUM CHANNEL INHIBITORS | MERCK SHARP & DOHME (US) | 2013-12-04 | — | — | EP | disclosed |
| US-7825131-B2 | Quinoline potassium channel inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-11-02 | — | — | US | disclosed |
| US-7825131-B2 | Quinoline potassium channel inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-11-02 | — | — | US | disclosed |
| US-7825131-B2 | Quinoline potassium channel inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-11-02 | — | — | US | disclosed |
| US-20070078154-A1 | Quinoline potassium channel inhibitors | MERCK SHARP & DOHME CORP. | 2007-04-05 | — | — | US | disclosed |
| US-20070078154-A1 | Quinoline potassium channel inhibitors | MERCK SHARP & DOHME CORP. | 2007-04-05 | — | — | US | disclosed |
| US-20070078154-A1 | Quinoline potassium channel inhibitors | MERCK SHARP & DOHME CORP. | 2007-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078154-A1 | Quinoline potassium channel inhibitors | KCNQ2, KCNQ1, KCNJ2 | KCNA5 15/4885KCNH2 4/4885GRIA2 1188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.